Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.46 |
| ▸ | TUBB | P07437 | 3/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.41 |
| ▸ | ALPL | P05186 | 3/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956393 | 1.00 | TUBB4A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29956187 | 0.86 | ENPP2 (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL263475 | 0.86 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4048673 | 0.86 | ENPP2 (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29951073 | 0.82 | L3MBTL1 (0.44) | GPR3FFAR4 | |
| SCHEMBL29952907 | 0.82 | GRM7 (0.39) | ABL1GPR3FFAR4 | |
| SCHEMBL30916838 | 0.81 | CA12 (0.46) | ABL1ALPLGPR3FFAR4CA12 | |
| SCHEMBL518510 | 0.81 | TUBB4A (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29385414 | 0.81 | TUBB4A (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12422184 | 0.80 | CA12 (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-07 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3810598-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| EP-1554258-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1500653-A1 | Substituted arylpyrazines | Neurogen Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | disclosed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | TUBB4A 3579/4885TUBB 3355/4885TUBA3C 3672/4885 |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | TUBB4A 4849/4885TUBB 4864/4885TUBA3C 4810/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | TUBB4A 4815/4885TUBB 4862/4885TUBA3C 4809/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TUBB4A 3579/4885TUBB 3355/4885TUBA3C 3672/4885 |
| US-10668067-B2 | Pyridine sulfonamides | TRPV1, TRPA1, TRPV5 | TUBB4A 2835/4885TUBB 2856/4885TUBA3C 2401/4885 |
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | CBR3, HCRTR1, CYP4F11 | TUBB4A 2047/4885TUBB 1423/4885TUBA3C 775/4885 |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | TUBB4A 3579/4885TUBB 3355/4885TUBA3C 3672/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TUBB4A 3579/4885TUBB 3355/4885TUBA3C 3672/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | TUBB4A 4813/4885TUBB 4866/4885TUBA3C 4796/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TUBB4A 3579/4885TUBB 3355/4885TUBA3C 3672/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | TUBB4A 3579/4885TUBB 3355/4885TUBA3C 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.